Table 1 Clinicopathological characteristics of node negative breast cancer patients from the Mainz cohort with available gene array and COX-2 immunostaining data (n = 193)
Characteristics | n | % |
|---|---|---|
Age at diagnosis | ||
<50 | 44 | 22.8 |
≥50 | 149 | 77.2 |
pT stage | ||
pT1 | 105 | 54.4 |
pT2 | 85 | 44.0 |
pT3 | 3 | 1.6 |
Histological grade | ||
G I | 41 | 21.2 |
G II | 105 | 54.4 |
G III | 47 | 24.4 |
Estrogen receptor status | ||
Negative | 45 | 23.3 |
Positive | 148 | 76.7 |
Progesterone receptor status | ||
Negative | 81 | 42.0 |
Positive | 112 | 58.0 |
Hormone receptor status 1 | ||
Negative | 39 | 20.2 |
Positive | 154 | 79.8 |
HER-2 status | ||
Negative | 167 | 86.5 |
Positive | 26 | 13.5 |
Death | ||
Of cancer | 30 | 15.5 |
Unrelated to cancer | 25 | 12.9 |
Surviving | 138 | 71.5 |
Relapse | 57 | 29.5 |
Regional | 21 | 10.9 |
Metastasis | 44 | 22.8 |
Contralateral | 5 | 2.6 |
No relapse | 136 | 70.5 |
COX-2 intensity score (IS) | ||
0 | 35 | 18.1 |
1 | 45 | 23.2 |
2 | 65 | 33.7 |
3 | 48 | 24.9 |
COX-2 proportion score (PS) | ||
0 | 35 | 18.1 |
1 | 24 | 12.4 |
2 | 42 | 21.8 |
3 | 33 | 17.1 |
4 | 59 | 30.6 |
COX-2 immunostaining score (product of IS and PS) | ||
0 | 35 | 18.1 |
1 | 11 | 5.7 |
2 | 22 | 11.4 |
3 | 16 | 8.3 |
4 | 30 | 15.5 |
6 | 20 | 10.4 |
8 | 23 | 11.9 |
9 | 9 | 4.7 |
12 | 27 | 14.0 |
COX-2 immunostaining status | ||
Negative | 145 | 75.1 |
Positive | 48 | 24.9 |